First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Providence Medical Foundation, Fullerton, California +12 locations
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT05303467
Recruiting
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of California San Francisco, San Francisco, California +4 locations
Conditions: Glioblastoma Multiforme, Recurrent Glioblastoma
Register for Updates
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT05592938
Recruiting
Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalen... Read More
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
05/09/2025
Locations: NYU Langone Health, New York, New York +9 locations
Conditions: Breast Cancer, Breast Cancer Recurrent
Register for Updates
The Long COVID-19 Wearable Device Study
NCT05741112
Recruiting
To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Scripps Research, La Jolla, California
Conditions: Long COVID, Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Long Covid19
Register for Updates
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
05/09/2025
Locations: Arizona Medical Clinic, Phoenix, Arizona +38 locations
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Register for Updates
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
NCT06047834
Recruiting
A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, described as neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS). This study has been designed to assess the pharmacokinetics (PK) and safety of the lofexidine in neonate... Read More
Gender:
ALL
Ages:
Between 0 hours and 6 days
Trial Updated:
05/09/2025
Locations: Marshall Health, Huntington, West Virginia
Conditions: Opioid Withdrawal (Disorder)
Register for Updates
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136
Recruiting
This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE). Participants with MPS IIIA will be enrolled in two planned cohorts, and additional participants with MPS IIIA may be enrolled in three... Read More
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
05/09/2025
Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California +3 locations
Conditions: Mucopolysaccharidosis Type IIIA
Register for Updates
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
NCT06338267
Recruiting
The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2025
Locations: Rush University Medical Center, Chicago, Illinois +2 locations
Conditions: Rett Syndrome
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
NCT06491550
Recruiting
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/09/2025
Locations: Research Site, Glendale, California +1 locations
Conditions: Healthy Participants
Register for Updates
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II
NCT06576427
Recruiting
This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/09/2025
Locations: Hartford Hospital, Hartford, Connecticut +11 locations
Conditions: Pulmonary Embolism
Register for Updates
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
NCT06706258
Recruiting
The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be de... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/09/2025
Locations: Memorial Hermann Texas Medical Center, Houston, Texas
Conditions: Acute Kidney Injury
Register for Updates
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
NCT06853171
Recruiting
This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
05/09/2025
Locations: Pillar Clinical Research- Little Rock, Little Rock, Arkansas +3 locations
Conditions: Psychiatric Disorders
Register for Updates